Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
New Approaches to Neuroblastoma Therapy Consortium
Innovative Therapies for Children with Cancer in Europe (ITCC)
Age
2–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.
Participants must be able to swallow capsules.
You may not be if
Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.
Participants must not have untreated tumor that has spread to the brain or spinal cord.
Participants must not have a serious active disease other than neuroblastoma.
Participants must not have a condition affecting absorption.
Participants must not have had prior aurora kinase inhibitor exposure.
Participants must not have a known allergy to the study treatment.
Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
